From Our Partners
Monday, June 27, 2022
News on Pathogens and Preparedness
Global Biodefense
  • Featured
  • COVID-19
  • Funding
  • Directory
  • Jobs
  • Events
  • Subscribe
No Result
View All Result
  • Featured
  • COVID-19
  • Funding
  • Directory
  • Jobs
  • Events
  • Subscribe
No Result
View All Result
Global Biodefense
No Result
View All Result
Home Industry News

Bavarian Nordic Completes Smallpox Vaccine Delivery to SNS

by Global Biodefense Staff
December 2, 2013

Bavarian Nordic recently announced it completed the delivery of 20 million doses of IMVAMUNE smallpox biodefense vaccine to the U.S. Strategic National Stockpile (SNS) for use in the event of a smallpox emergency in the U.S.

This order completion is the result of a decade-long research and development partnership between Bavarian Nordic and the U.S. government and fulfills the original contract awarded in 2007, valued at USD 549 million.

“Bavarian Nordic is proud to be a part of fulfilling a US government requirement for bioterrorism preparedness by delivering 20 million doses of IMVAMUNE,” said Anders Hedegaard, President and CEO of Bavarian Nordic. “This accomplishment shows that when resources and commitment are applied, industry and government can successfully work together to achieve great things.”

Since 2010, Bavarian Nordic has been delivering the vaccine to the SNS.  It is being stockpiled for emergency use in individuals with compromised immune systems, such as people with HIV or atopic dermatitis, including children and pregnant and nursing women, who are not recommended to take the previous generation vaccine due to increased risk for severe side effects.

In April, the U.S. government awarded Bavarian Nordic a new contract valued at up to USD 228 million to supply 8 million additional doses of IMVAMUNE needed to maintain the 20 million dose stockpile over time.

Background

Bavarian Nordic initiated the development of IMVAMUNE in 1999. After the U.S. terrorist attacks of 2001, the government expanded its investment in medicines and vaccines to protect against potential bioterrorism agents, by establishing the Project BioShield initiative. 

Although smallpox was eradicated worldwide, the government considers it a high-priority bioterrorism threat.  While traditional, replicating smallpox vaccines have been effective in eradicating the disease, they are not recommended for up to 25 percent of the population due to the risk of adverse events, including death and severe disability. Therefore, the U.S. government initiated a program to develop and procure a smallpox vaccine suitable for this special population.

IMVAMUNE is a non-replicating vaccine that, unlike traditional vaccines, cannot spread in the vaccinated person. Therefore, none of the serious side effects normally associated with traditional vaccines have been seen with IMVAMUNE. 

In 2003 and 2004, Bavarian Nordic received two contracts from the U.S. National Institute of Allergy and Infectious Diseases (NIAID), part of the National Institutes of Health (NIH), for the clinical development of IMVAMUNE.  In 2007, BARDA awarded the company a procurement contract to supply 20 million doses of the vaccine. 

In April 2013, BARDA awarded Bavarian Nordic a new contract valued at up to USD 228 million to supply 8 million additional doses of IMVAMUNE needed to maintain the 20 million dose stockpile over time. The first USD 110 million of the new order is secured, and the remaining portion will be secured based on availability of funds in 2014.

The company is continuing its work with BARDA on an enhanced freeze dried vaccine formulation, which is expected to increase flexibility for use in an emergency and reduce stockpiling costs based on a longer shelf life. 

IMVAMUNE has also been supplied to other government stockpiles around the world. Earlier this year, the vaccine was approved in the European Union under the trade name IMVANEX®.   In the U.S., registration studies are currently ongoing.

From Our Partners
Tags: ASPRBARDABioterrorismHHSSmallpoxStrategic National StockpileVaccines

Related Posts

UK Health Security Agency Widens Monkeypox Vaccine Umbrella for Outbreak Control
Medical Countermeasures

UK Health Security Agency Widens Monkeypox Vaccine Umbrella for Outbreak Control

June 21, 2022
Biodefense Industry News
Industry News

Tonix Pharmaceuticals Opens Advanced Development Center for Vaccine Programs

June 20, 2022
Monkeypox Cases Prompt Additional Contracts for Bavarian Nordic Vaccine
Medical Countermeasures

Monkeypox Cases Prompt Additional Contracts for Bavarian Nordic Vaccine

May 30, 2022
Novavax Missed Its Global Moonshot but Is Angling to Win Over mRNA Defectors
Industry News

Novavax Missed Its Global Moonshot but Is Angling to Win Over mRNA Defectors

May 26, 2022
Load More

Latest News

Poliovirus Detected in London Sewage: Response Measures Emphasize Wastewater Surveillance and Vaccination Gaps

Poliovirus Detected in London Sewage: Response Measures Emphasize Wastewater Surveillance and Vaccination Gaps

June 22, 2022
Monkeypox Diagnostics: CDC Authorizes Five Commercial Lab Companies

Monkeypox Diagnostics: CDC Authorizes Five Commercial Lab Companies

June 22, 2022
UK Health Security Agency Widens Monkeypox Vaccine Umbrella for Outbreak Control

UK Health Security Agency Widens Monkeypox Vaccine Umbrella for Outbreak Control

June 21, 2022
Influenza Research

New Way to Identify Influenza A Virus Lights Up When Specific Virus Targets are Present

June 20, 2022

Subscribe

  • About
  • Contact
  • Privacy
  • Subscribe

© 2022 Stemar Media Group LLC

No Result
View All Result
  • Featured
  • COVID-19
  • Funding
  • Directory
  • Jobs
  • Events
  • Subscribe

© 2022 Stemar Media Group LLC